Literature DB >> 11992881

Gabapentin attenuates superior oblique myokymia.

Robert L Tomsak1, Gregory S Kosmorsky, R John Leigh.   

Abstract

PURPOSE: To investigate therapeutic effects of oral gabapentin therapy on superior oblique myokymia.
DESIGN: Observational case series with measurement of visual acuity and eye movements before, during, and after therapy.
METHODS: Two adult patients with superior oblique myokymia, refractory to other therapies, were treated with gabapentin orally after informed consent was obtained. Eye movements were measured using the magnetic search coil technique.
RESULTS: Superior oblique myokymia completely resolved after starting gabapentin.
CONCLUSION: Gabapentin may be an effective treatment for superior oblique myokymia; a double-blind study seems justified.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992881     DOI: 10.1016/s0002-9394(02)01343-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

Review 1.  Superior oblique myokymia.

Authors:  Jorge C Kattah; Edmond J FitzGibbon
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

Review 2.  Topical timolol in the treatment of monocular oscillopsia secondary to superior oblique myokymia: a review.

Authors:  Christopher J Borgman
Journal:  J Optom       Date:  2013-08-02

3.  A 67-year-old woman with shaking of the world.

Authors:  Stephen J Turner; Paul Riordan-Eva; Steve Connor; Michael Samuel
Journal:  Digit J Ophthalmol       Date:  2008-06-15

Review 4.  Therapy of Vestibular Paroxysmia, Superior Oblique Myokymia, and Ocular Neuromyotonia.

Authors:  Michael Strupp; Marianne Dieterich; Thomas Brandt; Katharina Feil
Journal:  Curr Treat Options Neurol       Date:  2016-07       Impact factor: 3.598

Review 5.  Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus.

Authors:  Michael Strupp; Matthew J Thurtell; Aasef G Shaikh; Thomas Brandt; David S Zee; R John Leigh
Journal:  J Neurol       Date:  2011-04-02       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.